# Bayer (Germany)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/bayer-germany/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 38 |
| Citations | 1,978,111 |
| City | Leverkusen |
| Country | DE |
| Description | Bayer (Germany) is a research organisation in Leverkusen, DE. OpenAlex records 32,155 works and 1,978,111 citations for it. 7,550 researchers list it as their most recent affiliation. |
| Homepage | http://www.gesundheit.bayer.de/de/index.php |
| OpenAlex ID | https://openalex.org/I67348948 |
| Region | North Rhine-Westphalia |
| Researchers | 7,550 |
| ROR ID | https://ror.org/04hmn8g73 |
| Type | company |
| Works | 32,155 |

## University papers

Showing 12 of 13.

- [Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial](https://scholariq.org/papers/rivaroxaban-compared-with-standard-anticoagulants-for-the-treatment-of-acute/)
- [Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes](https://scholariq.org/papers/blood-pressure-and-cardiorenal-outcomes-with-finerenone-in-chronic-kidney/)
- [Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial](https://scholariq.org/papers/design-and-baseline-characteristics-of-the-finerenone-in-addition-to-standard-of/)
- [Validity and Utility of a Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression: A Review](https://scholariq.org/papers/validity-and-utility-of-a-hierarchical-composite-end-point-for-clinical-trials/)
- [Gαi2- and Gαi3-Specific Regulation of Voltage-Dependent L-Type Calcium Channels in Cardiomyocytes](https://scholariq.org/papers/g-i2-and-g-i3-specific-regulation-of-voltage-dependent-l-type-calcium-channels/)
- [Lack of Gα<sub>i2</sub>leads to dilative cardiomyopathy and increased mortality in β<sub>1</sub>-adrenoceptor overexpressing mice](https://scholariq.org/papers/lack-of-g-sub-i2-sub-leads-to-dilative-cardiomyopathy-and-increased-mortality-in/)
- [Finerenone in Persons with Chronic Kidney Disease without Diabetes](https://scholariq.org/papers/finerenone-in-persons-with-chronic-kidney-disease-without-diabetes/)
- [Effect of MANT-nucleotides on L-type calcium currents in murine cardiomyocytes](https://scholariq.org/papers/effect-of-mant-nucleotides-on-l-type-calcium-currents-in-murine-cardiomyocytes/)
- [Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases](https://scholariq.org/papers/finerenone-in-patients-with-chronic-kidney-disease-due-to-glomerular-diseases/)
- [Design and Baseline Characteristics of the FIND-CKD Trial: Efficacy of Finerenone on Kidney Disease Progression in People with Non-Diabetic CKD](https://scholariq.org/papers/design-and-baseline-characteristics-of-the-find-ckd-trial-efficacy-of-finerenone/)
- [Correction: Gα <sub>i2</sub> - and Gα <sub>i3</sub> -Specific Regulation of Voltage-Dependent L-Type Calcium Channels in Cardiomyocytes](https://scholariq.org/papers/correction-g-sub-i2-sub-and-g-sub-i3-sub-specific-regulation-of-voltage/)
- [Differential Modulation Of Cardiac L-type Calcium Currents By GαI2 And GαI3](https://scholariq.org/papers/differential-modulation-of-cardiac-l-type-calcium-currents-by-g-i2-and-g-i3/)

## University researchers

- [Nicole Rethemeier](https://scholariq.org/researchers/nicole-rethemeier/)
- [Sara Dizayee](https://scholariq.org/researchers/sara-dizayee/)

## University top topics

Showing 8 of 21.

- [Computational Drug Discovery Methods](https://scholariq.org/topics/computational-drug-discovery-methods/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Insect and Pesticide Research](https://scholariq.org/topics/insect-and-pesticide-research/)
- [Chemical Synthesis and Analysis](https://scholariq.org/topics/chemical-synthesis-and-analysis/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management/)
- [Pharmacogenetics and Drug Metabolism](https://scholariq.org/topics/pharmacogenetics-and-drug-metabolism/)
- [Analytical Chemistry and Chromatography](https://scholariq.org/topics/analytical-chemistry-and-chromatography/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.